Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.65 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.61 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.61 |
| ▸ | P2RY10 | O00398 | 5/20 | 0.59 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.54 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.48 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20582480 | 1.00 | PLA2G2C (0.65) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL666363 | 1.00 | PLA2G2C (0.65) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL22556278 | 1.00 | PLA2G2C (0.65) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL19878648 | 1.00 | PLA2G2C (0.65) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL446878 | 1.00 | PLA2G2C (0.65) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL28722720 | 1.00 | PLA2G2C (0.65) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL31096006 | 0.97 | PLA2G2C (0.61) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL28927332 | 0.95 | PLA2G2C (0.59) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL28927329 | 0.95 | PLA2G2C (0.59) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 | |
| SCHEMBL25394384 | 0.93 | PLA2G2C (0.73) | PLA2G2CLPAR1LPAR3P2RY10LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155780-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-6743781-B2 | COMPLEXING | TRANSGENE 6.A. (FR) | 2004-06-01 | — | — | US | disclosed |
| US-20010036927-A1 | Glycerolipid compounds useful for the transfer of an active substance into a target cell | BISCHOFF RAINER (SE) | 2001-11-01 | — | — | US | disclosed |
| US-6218370-B1 | USEFUL FOR CELL TRANSFECTION | TRANSGENE S.A. (FR) | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155780-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | PLA2G2C 102/4885LPAR1 33/4885LPAR3 43/4885 |
| US-20010036927-A1 | Glycerolipid compounds useful for the transfer of an active substance into a target cell | ACOX3, NSUN3, SLC43A1 | PLA2G2C 318/4885LPAR1 67/4885LPAR3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.